commercial-operations
(4)
David Schechter
David Schechter built a career at Merck by moving across categories while holding on to one operating idea: make the room sharper, then give people space to lead. His path from vaccines and diabetes to U.S. oncology shows what long-tenure leadership can look like when candor and autonomy travel together.
Adam Townsend
He spent two decades launching other people's medicines. Now he is running a biotech built to delete the antibodies that make patients sick - and taking the top job for the first time.
Doron Aspitz
Doron Aspitz is the President and CEO of Verix, a Santa Clara-based AI platform that helps pharmaceutical companies optimize their commercial operations through predictive analytics, HCP targeting, and GenAI-powered decision intelligence. A serial entrepreneur with 20+ years in technology leadership, he previously co-founded Blue Pumpkin Software - a workforce management company acquired by Witness Systems for ~$75 million in 2005. At Verix, he has built the Tovana platform, now trusted by global pharma giants including Bayer, Novartis, Roche, and GSK, bringing AI-driven commercial intelligence to the complex world of drug commercialization.
John Vitalie
John Vitalie is the CEO of Aktana, a San Francisco-based AI platform company that helps global life sciences organizations optimize commercial engagement with healthcare providers. A three-time software CEO with leadership stints at Salesforce, Oracle, and Siebel Systems, Vitalie brings a decade of pioneering AI in life sciences to a company building what it calls a Contextual Intelligence Engine - blending AI, human insight, and omnichannel orchestration to make every pharma sales interaction more timely and personalized. Recognized as one of the Top 25 Biotech CEOs of 2022 by the Healthcare Technology Report, he champions a philosophy that AI should augment human judgment, not replace it.